| case report | Q2782326 |
| scholarly article | Q13442814 |
| P2093 | author name string | Sanjay Kalra | |
| P2860 | cites work | Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial | Q28277510 |
| Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial | Q28286240 | ||
| Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial | Q28287325 | ||
| Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study | Q28293505 | ||
| Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration | Q28378259 | ||
| Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects | Q33441916 | ||
| Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) | Q33854032 | ||
| DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. | Q51379684 | ||
| The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. | Q51381364 | ||
| Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria | Q58448092 | ||
| LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects | Q83248884 | ||
| Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. | Q33982482 | ||
| Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study | Q34598940 | ||
| Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes | Q34835217 | ||
| One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr | Q34893192 | ||
| Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 | ||
| Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). | Q37235840 | ||
| Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing | Q37364896 | ||
| Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes | Q37767054 | ||
| GLP-1 based therapies: differential effects on fasting and postprandial glucose | Q37974712 | ||
| GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus | Q38040314 | ||
| Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes | Q42165729 | ||
| Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes | Q42169660 | ||
| Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein | Q43054066 | ||
| Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study | Q43255700 | ||
| Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes | Q44526985 | ||
| One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. | Q44865459 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes | Q45124469 | ||
| Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial | Q46344895 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea | Q46458866 | ||
| Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
| Psychological and quality of life changes in patients using GLP-1 analogues | Q48665369 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P304 | page(s) | 333-340 | |
| P577 | publication date | 2014-02-19 | |
| P1433 | published in | Diabetes Therapy | Q26853803 |
| P1476 | title | Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach | |
| P478 | volume | 5 |
| Q92270000 | Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force |
| Q92649404 | GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective |
| Q26823768 | GLP-1 receptor agonists: a review of head-to-head clinical studies |
| Q26752699 | Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future |
| Q35056339 | Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use. |
Search more.